CA2274581A1 - Oligonucleotide compositions and methods for the modulation of the expression of b7 protein - Google Patents

Oligonucleotide compositions and methods for the modulation of the expression of b7 protein Download PDF

Info

Publication number
CA2274581A1
CA2274581A1 CA002274581A CA2274581A CA2274581A1 CA 2274581 A1 CA2274581 A1 CA 2274581A1 CA 002274581 A CA002274581 A CA 002274581A CA 2274581 A CA2274581 A CA 2274581A CA 2274581 A1 CA2274581 A1 CA 2274581A1
Authority
CA
Canada
Prior art keywords
modulation
methods
protein
expression
oligonucleotide compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002274581A
Other languages
French (fr)
Other versions
CA2274581C (en
Inventor
C. Frank Bennett
Timothy A. Vickers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ionis Pharmaceuticals Inc
Original Assignee
Isis Pharmaceuticals Inc.
C. Frank Bennett
Timothy A. Vickers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc., C. Frank Bennett, Timothy A. Vickers filed Critical Isis Pharmaceuticals Inc.
Publication of CA2274581A1 publication Critical patent/CA2274581A1/en
Application granted granted Critical
Publication of CA2274581C publication Critical patent/CA2274581C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol

Abstract

Compositions and methods for the diagnosis, prevention and treatment of immune states and disorders amenable to treatment through modulation of T cell activation are provided. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with nucleic acids encoding B7 proteins.
CA002274581A 1996-12-31 1997-12-16 Oligonucleotide compositions and methods for the modulation of the expression of b7 protein Expired - Fee Related CA2274581C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/777,266 US6077833A (en) 1996-12-31 1996-12-31 Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US08/777,266 1996-12-31
PCT/US1997/023270 WO1998029124A1 (en) 1996-12-31 1997-12-16 Oligonucleotide compositions and methods for the modulation of the expression of b7 protein

Publications (2)

Publication Number Publication Date
CA2274581A1 true CA2274581A1 (en) 1998-07-09
CA2274581C CA2274581C (en) 2004-02-10

Family

ID=25109768

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002274581A Expired - Fee Related CA2274581C (en) 1996-12-31 1997-12-16 Oligonucleotide compositions and methods for the modulation of the expression of b7 protein

Country Status (10)

Country Link
US (1) US6077833A (en)
EP (1) EP0957926B1 (en)
JP (1) JP3471025B2 (en)
KR (1) KR100452105B1 (en)
AT (1) ATE289200T1 (en)
AU (1) AU720969B2 (en)
CA (1) CA2274581C (en)
DE (1) DE69732535T2 (en)
ES (1) ES2238083T3 (en)
WO (1) WO1998029124A1 (en)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033977A1 (en) * 1990-08-14 2004-02-19 Bennett C. Frank Oligonucleotide modulation of cell adhesion
US6369209B1 (en) * 1999-05-03 2002-04-09 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US7119184B2 (en) 1991-08-12 2006-10-10 Isis Pharmaceuticals, Inc. Oligonucleotides having A-DNA form and B-DNA form conformational geometry
CA2190304A1 (en) * 1995-12-15 1997-06-16 Elazar Rabbani Property effecting and/or property exhibiting compositions for therapeutic and diagnostic uses
US7115580B1 (en) * 1996-12-31 2006-10-03 Isis Pharmaceuticals, Inc. Antisense modulation of B7 protein expression
US6319906B1 (en) * 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US7572582B2 (en) 1997-09-12 2009-08-11 Exiqon A/S Oligonucleotide analogues
US6518017B1 (en) * 1997-10-02 2003-02-11 Oasis Biosciences Incorporated Combinatorial antisense library
US20030165888A1 (en) 2001-07-18 2003-09-04 Brown Bob D. Oligonucleotide probes and primers comprising universal bases for diagnostic purposes
JP2003517283A (en) * 1999-04-08 2003-05-27 オアシス バイオサイエンシーズ インコーポレイティッド Amplification and sequencing of primer pairs and their use
ATE334193T1 (en) * 1999-05-04 2006-08-15 Genethor Gmbh METHOD FOR REDUCING SPECIFIC IMMUNE REACTIONS
EP1085085A1 (en) * 1999-09-18 2001-03-21 Ahmed Dr. Sheriff Process for reducing specific immune reactions
EP2267029B1 (en) 1999-09-03 2016-06-15 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using Cadherin-11 modulating agents
EP1296643A4 (en) * 1999-09-17 2005-07-27 Isis Pharmaceuticals Inc Antisense modulation of transforming growth factor-beta expression
WO2002026757A2 (en) * 2000-09-26 2002-04-04 Hybridon, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
CA2790034A1 (en) * 2001-06-21 2003-01-03 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
US20050019915A1 (en) * 2001-06-21 2005-01-27 Bennett C. Frank Antisense modulation of superoxide dismutase 1, soluble expression
US20030054354A1 (en) * 2001-08-23 2003-03-20 Bennett C. Frank Use of antisense oligonucleotide libraries for identifying gene function
US20040044404A1 (en) * 2002-08-30 2004-03-04 Stucke Sean M. Retention coatings for delivery systems
US7960355B2 (en) * 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein
US7897582B2 (en) * 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
WO2005017163A2 (en) * 2003-08-15 2005-02-24 Imperial College Innovations Limited Phenotypic knockout of cell-surface proteins
WO2005112885A2 (en) * 2004-05-12 2005-12-01 Baxter International Inc. Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
EP1765294B1 (en) * 2004-05-12 2008-09-24 Baxter International Inc. Nucleic acid microspheres, production and delivery thereof
KR100721928B1 (en) 2004-11-05 2007-05-28 주식회사 바이오씨에스 Pharmaceutical composition for treating or preventing dermatitis comprising CpG oligodeoxynucleotide
MX2009001226A (en) 2006-08-04 2009-03-20 Baxter Int Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes.
CN101686939B (en) * 2007-04-17 2013-03-27 巴克斯特国际公司 Nucleic acid microparticles for pulmonary delivery
US8841429B2 (en) 2009-11-03 2014-09-23 Vivonics, Inc. Nucleic acid ligands against infectious prions
US8236570B2 (en) 2009-11-03 2012-08-07 Infoscitex Methods for identifying nucleic acid ligands
WO2011088148A1 (en) * 2010-01-12 2011-07-21 Isis Pharmaceuticals, Inc. Modulation of transforming growth factor-beta 1 expression
EP3757214B1 (en) 2014-04-01 2022-06-15 Biogen MA Inc. Compositions for modulating sod-1 expression
US10294454B2 (en) 2016-08-24 2019-05-21 General Electric Company Methods and kits for cell activation

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ209840A (en) * 1983-10-17 1988-11-29 Kaji Akira A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action
US5034506A (en) * 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4806463A (en) * 1986-05-23 1989-02-21 Worcester Foundation For Experimental Biology Inhibition of HTLV-III by exogenous oligonucleotides
US5194428A (en) * 1986-05-23 1993-03-16 Worcester Foundation For Experimental Biology Inhibition of influenza virus replication by oligonucleotide phosphorothioates
US5264423A (en) * 1987-03-25 1993-11-23 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5276019A (en) * 1987-03-25 1994-01-04 The United States Of America As Represented By The Department Of Health And Human Services Inhibitors for replication of retroviruses and for the expression of oncogene products
US5004810A (en) * 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5087617A (en) * 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5514788A (en) * 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US5459255A (en) * 1990-01-11 1995-10-17 Isis Pharmaceuticals, Inc. N-2 substituted purines
US6641809B1 (en) * 1990-03-26 2003-11-04 Bristol-Myers Squibb Company Method of regulating cellular processes mediated by B7 and CD28
US5166195A (en) * 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
US5135917A (en) * 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US5218105A (en) * 1990-07-27 1993-06-08 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5378825A (en) * 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
US5138045A (en) * 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
US5242906A (en) * 1991-04-22 1993-09-07 University Of North Carolina At Chapel Hill Antisense oligonucleotides against Epstein-Barr virus
US5539082A (en) * 1993-04-26 1996-07-23 Nielsen; Peter E. Peptide nucleic acids
AU661854B2 (en) * 1991-06-27 1995-08-10 Bristol-Myers Squibb Company CTL4A receptor, fusion proteins containing it and uses thereof
US5747034A (en) * 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
DE69333698T2 (en) * 1992-07-20 2005-12-01 Isis Pharmaceutical, Inc., Carlsbad PSEUDO HALF NODES FORMING RNA BY HYBRIDIZING ANTISSESEOLIGON NUCLEOTIDES TO TARGETED RNA SECONDARY STRUCTURES
US5585479A (en) * 1992-07-24 1996-12-17 The United States Of America As Represented By The Secretary Of The Navy Antisense oligonucleotides directed against human ELAM-I RNA
MX9306147A (en) * 1992-10-02 1994-06-30 Bristol Myers Squibb Co PHARMACEUTICAL COMPOSITION TO INHIBIT THE GROWTH OF TUMOR CELLS.
EP0711345A1 (en) * 1993-07-26 1996-05-15 Dana Farber Cancer Institute B7-2: ctl a4/cd 28 counter receptor
CA2168202A1 (en) * 1993-07-30 1995-03-16 Joseph Dougherty Efficient gene transfer into primary lymphocytes
AU7526894A (en) * 1993-08-16 1995-03-14 Arch Development Corporation B7-2: ctla4/cd28 counter receptor
AU7638894A (en) * 1993-09-03 1995-03-22 Miyuki Azuma B70(b7-2):ctla-4 bonding protein
JPH0779793A (en) * 1993-09-14 1995-03-28 Sumitomo Electric Ind Ltd Monoclonal antibody against b70 molecule
CA2188812A1 (en) * 1994-05-26 1995-12-07 Mark De Boer New methods and compounds for the selective modulation of antigen-specific t-cell responsiveness
EP0784482A2 (en) * 1994-06-07 1997-07-23 The Regents Of The University Of Minnesota Methods for inhibiting antigen specific t cell responses
CA2201592A1 (en) * 1994-10-03 1996-04-18 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system
WO1996015780A1 (en) * 1994-11-23 1996-05-30 Isis Pharmaceuticals, Inc. Compositions and methods for preventing and treating allograft rejection

Also Published As

Publication number Publication date
EP0957926A4 (en) 2002-01-23
AU720969B2 (en) 2000-06-22
AU5705198A (en) 1998-07-31
US6077833A (en) 2000-06-20
DE69732535D1 (en) 2005-03-24
CA2274581C (en) 2004-02-10
ATE289200T1 (en) 2005-03-15
ES2238083T3 (en) 2005-08-16
JP2000507833A (en) 2000-06-27
JP3471025B2 (en) 2003-11-25
DE69732535T2 (en) 2006-03-30
EP0957926A1 (en) 1999-11-24
KR100452105B1 (en) 2004-10-08
EP0957926B1 (en) 2005-02-16
KR20000062274A (en) 2000-10-25
WO1998029124A1 (en) 1998-07-09

Similar Documents

Publication Publication Date Title
CA2274581A1 (en) Oligonucleotide compositions and methods for the modulation of the expression of b7 protein
CA2177357A1 (en) PNA-DNA-PNA Chimeric Macromolecules
PL328563A1 (en) Oligonucleotides of modified sugar residues
CA2126691A1 (en) Gapped 2' modified oligonucleotides
WO1998055495A3 (en) Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
CA2174315A1 (en) Oligonucleotide modulation of multidrug resistance-associated protein
CA2347979A1 (en) Treatment of skin with adenosine or adenosine analog
EP1757621A3 (en) Compositions and methods for the treatment and diagnosis of immune disorders
CA2194761A1 (en) Immunomodulatory oligonucleotides
CA2294516A1 (en) Ikk-.beta. proteins, nucleic acids and methods
CA2295999A1 (en) Nik proteins, nucleic acids and methods
WO1998019167A3 (en) Cell stress regulated human mhc class i gene
EP1715035A3 (en) Synthetic polynucleotides encoding lysyl oxidase
CA2281895A1 (en) Ikb kinases
EP1571216A3 (en) Phosphodiesterase 8A
CA2294566A1 (en) Ikk-.alpha. proteins, nucleic acids and methods
ATE245190T1 (en) ROBO: A FAMILY OF POLYPEPTIDES AND NUCLEIC ACIDS EFFECTIVE IN NERVE CELL CONDUCTION
EP1757616A3 (en) Semaphorin receptors
EP0671470A3 (en) Trehalose releasing enzyme, DNA encoding therefor, their preparation and uses.
ZA9710163B (en) Novel carboxylesterase nucleic acid molecules, proteins and uses thereof.
CA2278808A1 (en) Methods for cultivating cells and propagating viruses
CA2146320A1 (en) Antisense oligonucleotide inhibition of the ras gene
CA2273855A1 (en) Novel feline fc epsilon receptor alpha chain nucleic acid molecules, proteins and uses thereof
AU1138699A (en) Dna demethylase, therapeutic and diagnostic uses thereof
TR199902434T2 (en) Bacterial plasmids.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20121217